Citius Oncology, Inc.
CTOR
$0.94
$0.011.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.11M | 5.61M | 3.94M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.11M | 5.61M | 3.94M | -- | -- |
| Cost of Revenue | 1.79M | 1.12M | 789.20K | -- | -- |
| Gross Profit | 5.32M | 4.49M | 3.15M | -- | -- |
| SG&A Expenses | 45.38M | 41.61M | 18.79M | 17.10M | 18.84M |
| Depreciation & Amortization | 4.01M | 2.29M | 573.40K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.58M | 49.13M | 26.32M | 23.52M | 25.48M |
| Operating Income | -47.47M | -43.52M | -22.38M | -23.52M | -25.48M |
| Income Before Tax | -45.87M | -41.95M | -22.58M | -23.70M | -25.64M |
| Income Tax Expenses | 189.90K | 561.40K | 1.06M | 1.06M | 936.60K |
| Earnings from Continuing Operations | -46.06 | -42.51 | -23.64 | -24.76 | -26.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.06M | -42.51M | -23.64M | -24.76M | -26.58M |
| EBIT | -47.47M | -43.52M | -22.38M | -23.52M | -25.48M |
| EBITDA | -38.75M | -31.57M | -4.68M | -- | -- |
| EPS Basic | -0.48 | -0.47 | -0.31 | -0.34 | -0.37 |
| Normalized Basic EPS | -0.30 | -0.29 | -0.19 | -0.20 | -0.23 |
| EPS Diluted | -0.48 | -0.47 | -0.31 | -0.34 | -0.37 |
| Normalized Diluted EPS | -0.30 | -0.29 | -0.19 | -0.20 | -0.23 |
| Average Basic Shares Outstanding | 373.79M | 337.46M | 308.98M | 293.07M | 284.37M |
| Average Diluted Shares Outstanding | 373.79M | 337.46M | 308.98M | 293.07M | 284.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |